drugset / Trial / NCT03641586
The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, food effect, and preliminary antitumor activities of BGB-283 in Chinese subjects with local advanced or metastatic malignant solid tumor.
Timeline
- Start
- 2015-10-12
- Primary completion
- 2016-12-06
- Completion
- 2019-03-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lifirafenib | Small molecule | 20 mg | — |
| Subject | Lifirafenib | Small molecule | 30 mg | — |